Presentation is loading. Please wait.

Presentation is loading. Please wait.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Published byJoy Lawrence Modified over 8 years ago

Similar presentations

Presentation on theme: "Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia."— Presentation transcript:

1 Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia by Alfonso Quintás-Cardama, Farhad Ravandi, Theresa Liu-Dumlao, Mark Brandt, Stefan Faderl, Sherry Pierce, Gautam Borthakur, Guillermo Garcia-Manero, Jorge Cortes, and Hagop Kantarjian Blood Volume 120(24):4840-4845 December 6, 2012 ©2012 by American Society of Hematology

2 Survival times of patients treated with standard intensive AML chemotherapy. Alfonso Quintás-Cardama et al. Blood 2012;120:4840-4845 ©2012 by American Society of Hematology

3 OS of patients treated with epigenetic therapy compared with patients treated with AI or other high-dose ara-C–containing regimens. Alfonso Quintás-Cardama et al. Blood 2012;120:4840-4845 ©2012 by American Society of Hematology

Download ppt "Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia."

Similar presentations

Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.

Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)

Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry by Gunnar Juliusson, Petar Antunovic,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13):4793-4807 December 15, 2008 ©2008 by American Society of Hematology.

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.
Comment on “Chromosomal Instability and Tumors Promoted by DNA Hypomethylation” and “Induction of Tumors in Mice by Genomic Hypomethylation” by Allen S.

Comment on “Chromosomal Instability and Tumors Promoted by DNA Hypomethylation” and “Induction of Tumors in Mice by Genomic Hypomethylation” by Allen S.
Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with.

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with.
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,
Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J

Megan Othus, Frederick R. Appelbaum, Stephen H. Petersdorf, Kenneth J
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,
Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.
Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.
Gupta V, Tallman MS, Weisdorf DJ

Gupta V, Tallman MS, Weisdorf DJ
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib by Keyur P. Patel, Kate J. Newberry, Rajyalakshmi.
How I treat elderly patients with myeloma

How I treat elderly patients with myeloma
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

Similar presentations

Ads by Google